The α7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU‐120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat
Authors:
- 22 August 2012
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 167 (2) , 421-435
Abstract
BACKGROUND AND PURPOSEAgonists selective for the α7 nicotinic acetylcholine (nACh) receptor produce anti‐hyperalgesic effects in rodent models of inflammatory pain, via direct actions on spinal pain circuits and possibly via attenuated release of peripheral pro‐inflammatory mediators. Increasingly, allosteric modulation of ligand‐gated receptors is recognized as a potential strategy to obtain desired efficacy in the absence of the putative adverse effects associated with agonist activation.EXPERIMENTAL APPROACHWe compared the anti‐hyperalgesic and anti‐inflammatory effects of the α7 nACh receptor agonist compound B with the positive allosteric modulator (PAM) PNU‐120596 and the standard non‐steroidal anti‐inflammatory drug (NSAID), diclofenac, in rats with hind paw inflammation induced by either formalin, carrageenan or complete Freund's adjuvant (CFA).KEY RESULTSWhen administered before carrageenan, both diclofenac (30 mg·kg−1) and PNU‐120596 (30 mg·kg−1) significantly reduced mechanical hyperalgesia and weight‐bearing deficits for up to 4 h. Compound B (30 mg·kg−1) also attenuated both measures of pain‐like behaviour, albeit less robustly. Whereas compound B and PNU‐120596 attenuated the carrageenan‐induced increase in levels of TNF‐α and IL‐6 within the hind paw oedema, diclofenac only attenuated IL‐6 levels. Established mechanical hyperalgesia induced by carrageenan or CFA was also partially reversed by compound B and PNU‐120596. However, diclofenac was considerably more efficacious. Formalin‐induced nocifensive behaviours were only reversed by compound B, albeit at doses which disrupted motor performance.CONCLUSIONS AND IMPLICATIONSα7 nACh receptor PAMs could prove to be useful in the treatment of inflammatory pain conditions, which respond poorly to NSAIDs or in situations where NSAIDs are contra‐indicated.Keywords
This publication has 48 references indexed in Scilit:
- Voltage- and Temperature-Dependent Allosteric Modulation of α7 Nicotinic Receptors by PNU120596Frontiers in Pharmacology, 2011
- Intrathecal injection of an alpha seven nicotinic acetylcholine receptor agonist attenuates gp120-induced mechanical allodynia and spinal pro-inflammatory cytokine profiles in ratsBrain, Behavior, and Immunity, 2010
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Physiological Concentrations of Choline Activate Native α7-Containing Nicotinic Acetylcholine Receptors in the Presence of PNU-120596 [1-(5-Chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea]The Journal of Pharmacology and Experimental Therapeutics, 2010
- An Allosteric Modulator of α7 Nicotinic Receptors, N-(5-Chloro-2,4-dimethoxyphenyl)-N′-(5-methyl-3-isoxazolyl)-urea (PNU-120596), Causes Conformational Changes in the Extracellular Ligand Binding Domain Similar to Those Caused by AcetylcholineMolecular Pharmacology, 2009
- Mammalian Nicotinic Acetylcholine Receptors: From Structure to FunctionPhysiological Reviews, 2009
- Nociceptors Are Interleukin-1β SensorsThe Journal of Neuroscience, 2008
- Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammationNature, 2002
- Ethical guidelines for investigations of experimental pain in conscious animalsPain, 1983